These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Muscarinic receptor blockade by pirenzepine: effect on prolactin secretion in man. Masala A; Alagna S; Devilla L; Rovasio PP; Rassa S; Faedda R; Satta A J Endocrinol Invest; 1982; 5(1):53-5. PubMed ID: 6808052 [TBL] [Abstract][Full Text] [Related]
5. Cholinergic-muscarinic receptors do not mediate growth hormone release in response to baclofen, a gamma-aminobutyric acid agonist, in humans. Coiro V; Volpi R; Dassò L; Marchesi C; Castelli A; Rossi G; Camellini L; Chiodera P Horm Metab Res; 1985 May; 17(5):260-1. PubMed ID: 3839204 [No Abstract] [Full Text] [Related]
6. Pirenzepine blunts the nocturnal growth hormone release in insulin dependent diabetes. Martina V; Tagliabue M; Maccario M; Bertagna A; Ghigo E; Massara F; Camanni F Horm Metab Res; 1987 Sep; 19(9):449-50. PubMed ID: 3692441 [No Abstract] [Full Text] [Related]
7. Cholinergic mediation in dermorphin-induced growth hormone secretion in man. degli Uberti EC; Trasforini G; Salvadori S; Margutti A; Bianconi M; Teodori V; Tomatis R; Pansini R Horm Res; 1986; 24(4):251-5. PubMed ID: 3781483 [TBL] [Abstract][Full Text] [Related]
8. Subclasses of muscarinic receptors and pirenzepine. Further experimental evidence. Hammer R Scand J Gastroenterol Suppl; 1982; 72():59-67. PubMed ID: 6957998 [No Abstract] [Full Text] [Related]
9. Inhibition by somatostatin of the release of growth hormone induced by lysine-vasopressin in normal subjects. Chiodera P; Coiro V Biomed Pharmacother; 1985; 39(6):334-7. PubMed ID: 2867793 [TBL] [Abstract][Full Text] [Related]
10. Muscarinic cholinergic modulation of insulin response to an intravenous glucose tolerance test in normal man. Coiro V; Chiodera P; Volpi R; d'Amato L; Camellini L; Rossi G; Pignatti D; Butturini U J Endocrinol Invest; 1986 Feb; 9(1):27-30. PubMed ID: 3517121 [TBL] [Abstract][Full Text] [Related]
11. [Vasopressin and somatotropin secretion in man]. Giordano G; Marugo M; Minuto F; Barreca T Arch Maragliano Patol Clin; 1970; 26(6):333-48. PubMed ID: 5537756 [No Abstract] [Full Text] [Related]
12. Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase. Gil DW; Wolfe BB J Pharmacol Exp Ther; 1985 Mar; 232(3):608-16. PubMed ID: 2579230 [TBL] [Abstract][Full Text] [Related]
14. Evidence that cholinergic receptors of muscarinic type may modulate vasopressin release induced by metoclopramide. Steardo L; Iovino M; Monteleone P; Bevilacqua M; Norbiato G J Neural Transm Gen Sect; 1990; 82(3):213-7. PubMed ID: 2248733 [TBL] [Abstract][Full Text] [Related]
15. Role of cholinergic receptors blockade by atropine on growth hormone (GH)--releasing hormone (GHRH)--induced GH release in active or surgically cured acromegaly. Giusti M; Lomeo A; Mazzocchi GC; Attanasio R; Sessarego P; Mignone D; Fortini P; Giordano G Minerva Endocrinol; 1988; 13(2):87-94. PubMed ID: 3139980 [No Abstract] [Full Text] [Related]
16. Nicotinic-cholinergic involvement in arginine-vasopressin response to insulin-induced hypoglycemia in normal men. Coiro V; Butturini U; Gnudi A; Delsignore R; Volpi R; Chiodera P Metabolism; 1986 Jul; 35(7):577-9. PubMed ID: 3523115 [TBL] [Abstract][Full Text] [Related]
17. Pirenzepine and exocrine secretions: a selective agent for gastric glands? Dobrilla G; Lucchin L; Comberlato M; Coruzzi G; Bertaccini G Hepatogastroenterology; 1983 Dec; 30(6):246-8. PubMed ID: 6144623 [TBL] [Abstract][Full Text] [Related]
18. Central administration of the muscarinic receptor subtype-selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouse. Caulfield MP; Higgins GA; Straughan DW J Pharm Pharmacol; 1983 Feb; 35(2):131-2. PubMed ID: 6131987 [No Abstract] [Full Text] [Related]